Homepage > Company > Media > Pharma News > 2019 > Amgen Announces 2019 Second Quarter Dividend

Amgen Announces 2019 Second Quarter Dividend

THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019, to all stockholders of record as of the close of business on May 17, 2019.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Mar 07, 2019

https://www.prnewswire.com/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...